Our results from preclinical xenogeneic models suggested that Dara, a CD38-directed therapeutic intervention, can prevent GVHD by inhibiting the proliferation, activation and differentiation of CD8+ cytotoxic T cells, which is line with previous studies and further confirms that specific activation of CD38brightCD8+ T cells is associated with the development of aGVHD. Here, CD8A is linked to graft versus host disease.